Drugs / Trehalose
Trehalose
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05593549 | Jan 2023 → Dec 2028 expected | type 2 diabetes mellitus | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT04663854 | Aug 2020 → Mar 2022 | Alzheimer disease | Mashhad University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1 | NCT02725957 | Mar → Jun 2016 | — | Bioblast Pharma Ltd. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03700424 | Aug 2020 → May 2022 | acute coronary syndrome | Mashhad University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT04226924 | Jun 2017 → Feb 2018 | oculopharyngeal muscular dystrophy | Bioblast Pharma Ltd. | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT02147886 | Jul 2014 → Oct 2016 | Machado-Joseph disease | Bioblast Pharma Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02015481 | Feb 2014 → Apr 2016 | oculopharyngeal muscular dystrophy | Bioblast Pharma Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT05136885 | Feb 2022 → Aug 2023 | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Completed | Missed primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT05743764 | Mar 2023 → Feb 2024 | dry eye syndrome | Huons Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03461575 | Jan → Jul 2018 | dry eye syndrome | Huons Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02328482 | Jan 2015 → Oct 2017 | oculopharyngeal muscular dystrophy | Bioblast Pharma Ltd. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06655441 | Mar → Dec 2026 expected | dry eye syndrome | Southern California College of Optometry at Marshall B. Ketchum University | Recruiting | No outcome recorded |
| Phase 4 | NCT05355064 | May → Aug 2022 | Parkinson disease | Neuromed IRCCS | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01575288 | May 2012 → Dec 2015 | arterial disorder | University of Colorado, Boulder | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05597436 | — | amyotrophic lateral sclerosis | Seelos Therapeutics, Inc. | No longer available | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT02800161 Comparator | Jun 2016 → Oct 2022 | bipolar depression | Biomedical Research Networking Center (CIBER) | Completed | No outcome recorded |
| Phase 4 | NCT05990712 Background | Sep 2023 → Jan 2024 | cataract, dry eye syndrome | Uptown Eye Specialists | Unknown | No outcome recorded |
| Phase 4 | NCT04704518 Comparator | Sep 2022 → Dec 2023 | — | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trehalose | “Regimen E will evaluate the safety and efficacy of a single study drug, SLS-005 (Trehalose injection, 90.5 mg/mL for intravenous infusion) in participants with ALS.” NCT05136885 ↗15“Trehalose 30 g for IV infusion administered every week over an additional 52 weeks” NCT02328482 ↗ “Cyclosporine 0.02%, trehalose 3%” NCT03461575 ↗ “Cyclosporine 0.02%, trehalose 3%” NCT05743764 ↗ |
| Known as | Cabaletta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02015481 ↗ |
| Known as | SLS-005 | “Regimen E will evaluate the safety and efficacy of a single study drug, SLS-005 (Trehalose injection, 90.5 mg/mL for intravenous infusion) in participants with ALS.” NCT05136885 ↗ |
| Known as | SLS-005 Intravenous Trehalose Injection 90.5 mg/mL | “SLS-005 Intravenous Trehalose Injection 90.5 mg/mL” NCT05597436 ↗ |
| Action | Inhibit | “its inhibitory effects on β-amyloid formation in AD” NCT04663854 ↗ |
| Modality | Small molecule | “Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates.” NCT03700424 ↗ |
| Route | Oral | “Oral Trehalose Therapy to Reverse Arterial Aging in Middle-Aged and Older Adults” NCT01575288 ↗ |